Illumina expands Billion Cell Atlas program with new AI drug developers
Illumina expanded its Billion Cell Atlas alliance by adding three new members, including AI-native drug developer Formation Bio, to leverage genome-wide perturbation data for drug discovery. The program, originally launched in January 2026 with founding members AstraZeneca, Merck, and Eli Lilly, has now sequenced over 350 million cells and generated six petabytes of genomic data across more than 200 disease-relevant cell lines.
Key figures
- Cell lines
- 200
- Data volume
- six petabytes
- New members
- 3
- Target cells
- one billion
- Cells sequenced
- 350 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.